This announcement is a separate document:
宜明昂科-B：自願公告 – IMM01（替達派西普）聯合阿扎胞苷獲國家藥監局批准進行CMML一線治療的III期臨床試驗
IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR A PHASE III CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE FOR THE FIRST-LINE TREATMENT OF CMML
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.